Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia

Mendus, a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the company’s lead program, vididencel, for